The South African diabetes market is growing rapidly, primarily as a result of higher diagnosis rates. This is due to increased access to healthcare. Many type 2 diabetics are shifting towards the use of insulin along with their oral treatment. In 2006, 43.0 per cent of type II diabetics were using the more expensive insulin in addition to the oral treatment. This trend is significantly boosting the revenues of the anti-diabetic pharmaceutical market.